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31 Abstract 
 
32 Background:  Omalizumab,  an  anti-immunoglobulin  E  (IgE)  monoclonal  antibody, 
 
33 inhibits the binding of circulating IgE to mast cells and basophils, resulting in fewer 
 
34 episodes of airway inflammation, asthma symptoms, and exacerbations in patients with 
 
35 severe allergic asthma. Treatment of patients with asthma using omalizumab increases 
 
36 serum total IgE levels. However, little is known about the influence of omalizumab on 
 
37 allergen-specific IgE. 
 
38 Methods: Total IgE and allergen-specific IgE in 47 adult patients with severe asthma 
 
39 were measured with a fluorescent enzyme immunoassay (ImmunoCAP-FEIA) before 
 
40 and after omalizumab treatment. 
 
41 Results: Treatment with omalizumab increased total and allergen-specific IgE levels. 
 
42 The increases in allergen-specific IgE by class category after omalizumab treatment 
 
43 were   positively  correlated   with   baseline   allergen-specific   IgE   positivity  before 
 
44 omalizumab  treatment.  The  mean  changes  in  allergen-specific  IgE  levels  after 
 
45 omalizumab treatment were also correlated with baseline allergen-specific IgE levels 
 
46 before omalizumab treatment. The mean changes in total IgE levels were positively 
 
47 correlated with the mean changes in IgE levels against Dermatophagoides pteronyssinus, 
 
48 crude house dust, Japanese cedar, and moth.  Omalizumab markedly influenced the 
 
49 negative-to-positive  seroconversion  rate  for  IgE  against  Japanese  cedar  (30.8%), 
 
50 candida  (29.0%),  and  moth  (28.0%).  Finally,  all  patients  with  negative-to-positive 
 
51 seroconversion for Japanese cedar-specific IgE had cedar pollinosis before beginning 
 
52 omalizumab treatment. 
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53 Conclusions: The changes in allergen-specific IgE levels after omalizumab treatment 
 
54 may be dependent on the baseline allergen-specific IgE levels. Our data may indicate 
 
55 the presence of undetectable but functional allergen-specific IgE in these patients. 
 
56 
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57 Introduction 
 
58 Immunoglobulin E (IgE) discovered by Ishizaka [1] and Johansson [2] in 1966, 
 
59 plays a key role in the allergic reaction. Total and allergen-specific IgE level are helpful 
 
60 for diagnosing allergic diseases such as asthma, allergic rhinitis, and atopic dermatitis. 
 
61 IgE is a critical factor for the development of bronchial hyperresponsiveness in patients 
 
62 with asthma [3]. Several epidemiological studies have demonstrated that the total IgE 
 
63 level is higher in patients with asthma than in those without asthma [4-6]. In addition, 
 
64 the total IgE level in children with severe asthma is significantly higher than in children 
 
65 with mild to moderate asthma [7]. Global multicenter studies, such as SARP (Severe 
 
66 Asthma Research Program) and ENFUMOSA (European Network for Understanding 
 
67 Mechanisms of Severe Asthma), have demonstrated that there is no correlation between 
 
68 the total IgE level and asthma severity [8,9]. Serum total IgE levels peak during early 
 
69 adolescence and decrease with age [10-12]. However, longitudinal changes in IgE level 
 
70 are  heterogeneous  among  patients  with  adult  asthma.  Recently,  we  found  that 
 
71 longitudinal increases in total IgE levels are associated with poor disease control in 
 
72 patients with adult asthma [13]. However, the association between total IgE level and 
 
73 asthma control is not fully elucidated. Moreover, the association between 
 
74 allergen-specific IgE levels and asthma severity remains unknown. 
 
75 Omalizumab, a  humanized anti-human  IgE monoclonal antibody, is  an  adjunct 
 
76 treatment option for severe persistent allergic IgE‑mediated asthma in addition to the 
 
77 optimized standard therapy in patients with asthma aged 6 years and older. The clinical 
 
78 effects  of  omalizumab  on  patients  with  severe  asthma  revealed  that  IgE-mediated 
 
79 mechanisms,  which  can  be  suppressed  by neither  steroids  nor  leukotriene  receptor 
 
80 antagonists, play an important role in severe asthma. Omalizumab reduces free IgE 
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81 levels by approximately 95% by binding to the Cε3 region on free IgE, thereby blocking 
 
82 the binding of free IgE to its specific high-affinity receptor on mast cells, basophils, and 
 
83 any  other  cells  expressing  IgE  receptors.  Omalizumab  does  not  interact  with 
 
84 membrane-bound IgE. By reducing IgE levels, omalizumab leads to the downregulation 
 
85 of FcεRI on mast cells and basophils [14]. Omalizumab has a long half-life (19 to 22 
 
86 days), in part due to its slow removal by the hepatic reticuloendothelial system [15]. The 
 
87 half-life of omalizumab-bound IgE is longer than that of free IgE [16], and clinical tests 
 
88 cannot   discriminate   between   free IgE   and omalizumab-bound IgE.   Therefore 
 
89 administration of omalizumab generally increases serum IgE levels in patients with 
 
90 asthma   [17].   Several   reports   have   measured   free   IgE   levels   separately   from 
 
91 omalizumab-bound  IgE  [18,19];  however,  these  studies  did  not  involve  a  clinical 
 
92 setting. 
 
93 Although  omalizumab  is known to increase the clinically detectable  total  IgE 
 
94 levels,  changes  in  allergen-specific  IgE  levels  have  not  been  investigated  thus  far. 
 
95 Therefore, we observed the changes in allergen-specific IgE after omalizumab treatment 
 
96 and the influence of omalizumab treatment on these changes. 
97 
98 
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99 Material and Methods 
 
100 Study Participants 
 
101 Eighty nine patients with severe adult asthma were treated with omalizumab for at 
 
102 least 4 months in the Showa University Hospital, Japan from April 2009 to March 2014. 
 
103 After excluding 42 patients owing to lack of data regarding total and/or allergen-specific 
 
104 IgE levels, 47 patients were included in the study. Thirty patients with asthma who were 
 
105 not receiving omalizumab were included in the control group. The data for total and 
 
106 allergen-specific  IgE  levels  were  retrospectively  collected.  Asthma  was  diagnosed 
 
107 according to criteria of the Global Strategy for Asthma Management and Prevention by 
 
108 the Global Initiative for Asthma (GINA guideline) [20]. Japanese cedar pollinosis was 
 
109 diagnosed according to clinical symptoms and the presence of Japanese cedar-specific 
 
110 IgE.  Patients  with  chronic  obstructive  pulmonary  disease  or  other  lung  diseases, 
 
111 smoking history >20 pack-years, vocal cord dysfunction, or neurological disease were 
 
112 excluded. Diagnoses for perennial allergic rhinitis and seasonal cedar pollinosis were 
 
113 based on a clinical history and positive serum allergen-specific IgE test results. The 
 
114 baseline data included demographic details (age, sex, and basal body mass index [BMI]), 
 
115 clinical  features  (age  at  onset),  smoking  status  (ex-smoker,  current  smoker,  or 
 
116 nonsmoker), Asthma Control Test score, spirometry, and fractional exhaled nitric oxide 
 
117 (FeNO). BMI was defined as weight/height2 in kg/m2. The study protocol was reviewed 
 
118 and approved by the Showa University ethics committee, and written informed consent 
 
119 
 
120 
was obtained from each subject. 
 
121 Study Design 
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122 Omalizumab was administered subcutaneously at 2- or 4-week intervals depending 
 
123 on the patient’s body weight and total IgE level at screening. Blood samples were 
 
124 obtained before and after omalizumab treatment. Total IgE levels ranged 30 to 700 
 
125 IU/mL.  The  clinical  effectiveness  of  omalizumab  was  assessed  with  The  Global 
 
126 Evaluation of Treatment Effectiveness (GETE) by the physician at 16 weeks [21,22]. 
 
127 The GETE has five categories: 1. Complete control of asthma; 2. Marked improvement 
 
128 of asthma; 3. Discernible but limited improvement in asthma; 4. No appreciable change 
 
129 in asthma; and 5. Worsening of asthma. The first two levels of the GETE were used to 
 
130 
 
131 
define a treatment response. 
 
132 Data collection 
 
133 Blood was collected from the patients at 2 time-points: before beginning treatment 
 
134 with omalizumab, and shortly before the omalizumab injection at least 16 weeks or a 
 
135 maximum of 30 weeks after treatment with omalizumab. The blood collection period 
 
136 among control patients ranged 20 to 40 weeks. The serum total and allergen-specific 
 
137 IgE levels were measured with a fluorescent enzyme immunoassay (ImmunoCAP-FEIA, 
 
138 Phadia,  Freiburg,  Germany).  Allergen-specific  IgE  levels  were  determined  for  11 
 
139 aeroallergens: cocksfoot, ragweed, Cryptomeria japonica (Japanese cedar), 
 
140 Dermatophagoides  pteronyssinus  (Der  p),  crude  house  dust,  Aspergillus  fumigatus 
 
141 (aspergillus), Candida albicans (candida), Alternaria alternate (alternaria), cat dander, 
 
142 dog dander, and moth. Allergen-specific IgE levels were classified into five categories: 
 
143 Class 0, <0.35 kU/L, Class 1, 0.35–0.69 kU/L, Class 2, 0.70–3.49 kU/L, Class 3, 3.50– 
 
144 17.49 kU/L, Class 4, 17.50–49.99 kU/L, Class 5, 50.00–100.00 kU/L, Class 6, >100.00 
 
145 kU/L. The changes in total IgE (∆tIgE) or allergen-specific IgE (∆sIgE) were calculated 
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146 as   follows:   Total   IgE   after   omalizumab   –   total   IgE   before   omalizumab   or 
 
147 allergen-specific IgE after omalizumab – allergen-specific IgE before omalizumab. 
 
148 However, ∆sIgE were assessed only in the participants whose allergen-specific IgE 
 
149 levels  were  higher  than  0.35  kU/L  after  omalizumab  treatment.  Sensitization  was 
 
150 defined as an allergen-specific IgE level ≥0.35 kU/L. 
 
151 Spirometry was performed using an AS-302 spirometer (Minato Medical Science 
 
152 Co.,  Ltd.,  Osaka,  Japan)  in  accordance  with  American  Thoracic  Society/European 
 
153 Respiratory Society guidelines [23] to determine FEV1, forced vital capacity (FVC), and 
 
154 FEV1/FVC  (FEV1%).  FeNO  was  measured  using  a  portable  device  (NIOX  MINO, 
 
155 
 
156 
Aerocrine AB, Solna, Sweden) at an expiratory flow rate of 50 mL/s for 10 s. 
 
157 Statistical Analysis 
 
158 The results are expressed as mean ± standard deviation or standard error of the 
 
159 mean for continuous variables. Statistical analyses were performed using JMP version 
 
160 10 (SAS Institute Inc., Cary, NC, USA). The Pearson’s correlation coefficient (r) and 
 
161 Spearman  rank  order  correlation  coefficient  was  used  to  measure  the  correlation 
 
162 between  the  allergen-specific  IgE  positivity  before  omalizumab  treatment  and  the 
 
163 percent increase in allergen-specific IgE levels by class after omalizumab treatment, the 
 
164 correlation  between the  baseline levels  of  allergen-specific  IgE  before  omalizumab 
 
165 treatment and the mean ∆sIgE, and the correlation between the mean ∆tIgE and the 
 
166 mean  ∆sIgE.  The  differences  in  the  continuous  variables  were  analyzed  using  the 
 
167 Wilcoxon rank sum test or Kruskal-Wallis test, and the differences in the categorical 
 
168 variables were analyzed using the Pearson χ2  tests. A P value <0.05 was considered 
 
169 significant for all statistical assessments. 
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171 Results 
 
172 Study participants 
 
173 The patient demographics are shown in Table 1. All participants in the omalizumab 
 
174 group underwent treatment step 4 and above according to the GINA guidelines before 
 
175 and after omalizumab treatment. In the control group, 20 patients underwent treatment 
 
176 step 3, 7 patients underwent treatment step 4, and 3 patients underwent treatment step 5. 
 
177 There were significant differences in the ACT score, %FVC, and %FEV1  between the 
 
178 control group and the omalizumab group. Meanwhile, no difference was observed in 
 
179 peripheral eosinophils and total IgE levels. No patient was diagnosed with perennial 
 
180 conjunctivitis.  Twenty-six  patients  (55.3%)  were  classified  as  showing  “Complete 
 
181 control of asthma” or “Marked improvement of asthma” according to the GETE criteria 
 
182 at 16 weeks of the omalizumab treatment, indicating the omalizumab responders. Ten 
 
183 
 
184 
patients owned dogs, two patients owned cats, and one patient owned a bird. 
 
185 Changes in Specific-IgE after Omalizumab Treatment 
 
186 The prevalence of allergen-specific IgE is shown in Figure 1. Sensitization was 
 
187 defined as an allergen-specific IgE level ≥0.35 kU/L. Der p-specific IgE (76.6%), crude 
 
188 house dust-specific IgE (76.6%), and cedar-specific IgE (71.7%) showed high positivity. 
 
189 ∆tIgE  and  ∆sIgE  after  omalizumab  treatment  are  shown  in  Table  2.  There  were 
 
190 significant differences in ∆tIgE and ∆sIgE except for ∆alternaria-specific IgE between 
 
191 the control group and the omalizumab group. Specific IgE levels for alternaria were 
 
192 lower than 0.35 kU/L in 41 of 44 patients before omalizumab treatment. The raw data 
 
193 for tIgE and sIgE before and after omalizumab treatment are shown in Table E1. As the 
 
194 durations of omalizumab treatment varied widely, we determined the differences in 
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195 ∆tIgE and ∆sIgE between the early time-point group, at 16 to 22 weeks, and the late 
 
196 time-point group, at 23 to 30 weeks. No difference was observed in ∆tIgE and ∆sIgE for 
 
197 Der p, crude house dust, Japanese cedar, aspergillus, candida, dog, and moth between 
 
198 the  early  time-point  group  and  the  late-point  group  (Table  E2).  The  increase  in 
 
199 allergen-specific IgE levels by one or more classes after omalizumab treatment is shown 
 
200 in  Figure  2.  The  percent  increase  in  Der  p-specific  IgE  (38.3%),  crude  house 
 
201 dust-specific IgE (36.2%), cedar-specific IgE (38.6%), candida-specific IgE (33.3%), 
 
202 
 
203 
and moth-specific IgE (26.7%) was considerably high. 
 
204 Correlation between Allergen-Specific  IgE before Omalizumab and Changes in 
 
205 Allergen-Specific IgE after Omalizumab 
 
206 We investigated the correlations between allergen-specific IgE before omalizumab 
 
207 treatment and ∆sIgE. Figure 3A shows a positive correlation between allergen-specific 
 
208 IgE positivity before omalizumab treatment and the percent increase in allergen-specific 
 
209 IgE by class after omalizumab treatment (R = 0.833, P = 0.001). A positive correlation 
 
210 was also observed between baseline allergen-specific IgE levels before omalizumab 
 
211 treatment and ∆sIgE (Figure 3B; R = 0.825, P = 0.001). In addition, there was no 
 
212 significant  difference  in  the  percent  increase  between  each  individual  allergen 
 
213 specific-IgE (Figure E1). Neither ∆tIgE nor ∆sIgE were associated with the cumulative 
 
214 doses of omalizumab (data not shown). 
 
215 Next, we investigated the correlation between ∆tIgE and ∆sIgE. Analyses were 
 
216 performed in patients with detectable allergen-specific IgE levels (>0.35 kU/L) after 
 
217 omalizumab treatment. A positive correlation was observed between ∆tIgE and mean 
 
218 changes in IgE levels against Der p, crude house dust, cedar, and moth (Table 3). 
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219 However, no correlation was detected between ∆tIgE and mean changes in IgE levels 
 
220 against aspergillus, candida, and dog dander (Table 3), despite the high correlation 
 
221 
 
222 
coefficient between ∆tIgE and mean changes in aspergillus-IgE. 
 
223 Negative-to-Positive Seroconversion in Allergen-Specific IgE 
 
224 Finally, we investigated the negative-to-positive seroconversion rate for 
 
225 allergen-specific IgE, which was class 0 at baseline, after omalizumab treatment. The 
 
226 numbers of samples at class 0 at baseline was 11 for Der p, 11 for HD, 13 for Japanese 
 
227 cedar, 28 for cocksfoot, 36 for ragweed, 31 for aspergillus, 31 for candida, 41 for 
 
228 alternaria, 36 for cat  dander, 33 for dog dander, and 25 for moth. Highly marked 
 
229 negative-to-positive  seroconversion  rates  for  IgE  against  Japanese  cedar  (30.8%), 
 
230 candida (29.0%), and moth (28.0%) were observed (Figure 4). Intriguingly, all patients 
 
231 with  negative-to-positive  seroconversion  for  Japanese  cedar-specific  IgE  had  cedar 
 
232 pollinosis even before beginning omalizumab treatment. The blood was collected in the 
 
233 pollen season from 1 of 4 patients who showed cedar-specific IgE seroconversion after 
 
234 
 
235 
omalizumab treatment. 
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236 Discussion 
 
237 This study examined changes in serum allergen-specific IgE levels in patients with 
 
238 adult asthma after omalizumab treatment. We found that the changes in allergen-specific 
 
239 IgE after omalizumab were positively correlated with the level of allergen-specific IgE 
 
240 before  omalizumab  treatment,  but  not  the  allergen  specificity.  To  the  best  of  our 
 
241 knowledge,  this  study  is  the  first  to  elucidate  the  influence  of  omalizumab  on 
 
242 allergen-specific IgE in patients with severe adult asthma. 
 
243 We found positive correlations between ∆tIgE and mean changes in the IgE levels 
 
244 against Der p, crude house dust, Japanese cedar, and moth. Generally, the total IgE level 
 
245 reflects both specific and unspecific IgE. Previous birth cohort studies showed that the 
 
246 evolution of total IgE was extremely heterogeneous but parallel with that of airborne 
 
247 allergen-specific  IgE  [24,25],  indicating  that  changes  in  total  IgE  is  dependent  on 
 
248 antigen-specific  IgE,  in  particular,  allergen-specific  IgE.  Although  both  ∆tIgE  and 
 
249 ∆sIgE  were  mostly  influenced  by  omalizumab,  our  data  are  consistent  with  these 
 
250 previous data. However, there was no correlation between ∆tIgE and the mean changes 
 
251 in the IgE levels against candida and dog dander. This suggests that ∆tIgE may be 
 
252 dependent on ∆sIgE, for which the baseline positivity was relatively high. 
 
253 In this study, specific IgE levels against several allergens, which were below 0.35 
 
254 kU/L before omalizumab treatment, increased to above 0.35 kU/L, and these patients 
 
255 showed negative-to-positive seroconversion after omalizumab treatment. In particular, 
 
256 negative-to-positive seroconversion was frequently observed for IgE against Japanese 
 
257 cedar, candida, and moth. IgE positivity for these specific-allergens was considerably 
 
258 high before omalizumab treatment. Intriguingly, although Der p-specific IgE and house 
 
259 dust-specific IgE showed a high positivity similar to Japanese cedar-specific IgE, no 
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260 negative-to-positive seroconversion was observed for Der p-specific IgE and house 
 
261 dust-specific IgE. Further studies with a large sample size are necessary to clarify these 
 
262 findings.  Interestingly,  all  4  patients  with  negative-to-positive  seroconversion  for 
 
263 Japanese cedar-specific IgE after omalizumab treatment were diagnosed with cedar 
 
264 pollinosis   before   omalizumab   treatment,   indicating   the   presence   of   functional 
 
265 allergen-specific IgE despite the level being maintained below 0.35 IU/L. However, we 
 
266 assume that the seroconverted sIgE do not have clinical significance in patients treated 
 
267 with omalizumab because they are not free to bind to mast cells and basophils. 
 
268 Recently, omalizumab was found to be effective in treating patients with severe 
 
269 non-atopic  asthma  who  did  not  respond  to  a  skin-prick  test  and/or  with  negative 
 
270 allergen-specific IgE results [26-28]. One reason for the effectiveness of omalizumab in 
 
271 patients with non-atopic asthma may be the presence of local allergen-specific IgE. In 
 
272 fact, Mouthuy et al reported that both total IgE and Der p-specific IgE in sputum were 
 
273 significantly  increased  in  patients  with  non-atopic  asthma  compared  to  healthy 
 
274 non-atopic  participants  [29].  Our  results  indicate  that  the  presence  of  undetectable 
 
275 allergen-specific  IgE  due  to  extremely low  levels  could  be  another  reason  for  the 
 
276 effectiveness of omalizumab in patients with non-atopic asthma. 
 
277 Currently,  levels  of  specific  IgE  higher  than  0.11  kU/L can  be  detected  using 
 
278 ImmunoCAP-FEIA  in  a  clinical  setting  in  Japan.  However,  patients  who  began 
 
279 omalizumab  treatment  before  2011  showed  levels  of  specific  IgE  ≥0.35  kU/L. 
 
280 Therefore, for the purpose of this study, sensitization was defined as a specific IgE 
 
281 level ≥0.35 kU/L. Extremely low specific IgE levels in combination with the methods 
 
282 used to measure these levels could be important. ImmunoCAP is the most common 
 
283 method used to measure total and specific IgE levels. An alternative assay is the 
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284 IMMULITE 2000 3gAllergy™ (IMMULITE) (Siemens Healthcare Diagnostics Inc., 
 
285 USA). IMMULITE employs liquid-phase kinetics in a bead format, and 
 
286 chemiluminescent enzyme immunoassay. The allergens are covalently attached to a 
 
287 soluble polymer matrix in IMMULITE and to a solid column in ImmunoCAP. The 
 
288 liquid-phase allergens increase the number of binding sites and their accessibility to the 
 
289 allergen-specific IgE. In addition, IMMULITE has a wide measurement range from 0.1 
 
290 IUA/mL to 500 IUA/mL and a high degree of sensitivity [30-32]. Although the overall 
 
291 advantages  of  IMMULITE over  ImmunoCAP have not  been studied, IMMULITE 
 
292 seems to be a promising methodology with applicability in clinical settings. In this 
 
293 study, artificial increases in IgE by omalizumab shed light on the presence of clinically 
 
294 functional  class  0  allergen-specific  IgE  levels.  Therefore,  advances  in  the  current 
 
295 methods used to measure high-sensitive IgE and re-examination of the class 0 IgE 
 
296 level is necessary. 
 
297 This study contains several limitations that need to be acknowledged. First, the 
 
298 time-points of blood collection were not constant. The blood collections were performed 
 
299 from week 16 up to  week  30  after  beginning  omalizumab treatment.  Omalizumab 
 
300 treatment rapidly increases and then gradually decreases total IgE levels [33]. However, 
 
301 there is no previous report that describes the time-course of total and specific IgE levels 
 
302 after omalizumab treatment. If samples were collected when the IgE level peaked, the 
 
303 total and allergen-specific IgE levels could have been higher. In addition, the frequency 
 
304 of  negative-to-positive  seroconversion  for  allergen-specific  IgE  after  omalizumab 
 
305 treatment could further increase. However, we demonstrated no difference in ∆sIgE 
 
306 between the early time-point group and the late time-point group, thus, we believe that 
 
307 even if blood was collected at the optimum time-point, the positive correlation observed 
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308 between  changes  in  allergen-specific  IgE  after  omalizumab  treatment  and  baseline 
 
309 levels of allergen-specific IgE would not change. A previous study demonstrated that 
 
310 early changes in total IgE levels can be used as a predictor of future responders to 
 
311 omalizumab [34]. In this study, only a single time-point was used: post omalizumab 
 
312 treatment. Therefore, we could not assess the relationship between ∆sIgE and major 
 
313 outcome variables of omalizumab, such as pulmonary function, symptom scores, and 
 
314 oral corticosteroid use. Measurements of sIgE at different time-points would provide 
 
315 further elucidation of the influence of omalizumab on sIgE. Second, this study involved 
 
316 a small sample size. Omalizumab is an expensive medicine, and the opportunities to 
 
317 administer this drug are limited even for patients with uncontrolled asthma. Therefore, it 
 
318 was relatively difficult to collect enough samples in a real life setting. In particular, it is 
 
319 further difficult to determine the frequency of negative-to-positive seroconversion for 
 
320 allergen-specific IgE, because only those patients sensitized to perennial allergens are 
 
321 indicated  for  omalizumab  treatment.  Third,  this  study  did  not  consider  seasonal 
 
322 variations in IgE levels. The prevalence of cedar pollinosis in the participants of this 
 
323 study was 61.7%. Total IgE should increase in participants with cedar pollinosis in the 
 
324 Japanese cedar season, mostly March and April, and just after this season. We showed 
 
325 that  the  percent  increase  in  cedar-specific  IgE,  which  was  susceptible  to  seasonal 
 
326 variations, did not significantly differ from those observed for the other ∆sIgE. Thus, 
 
327 even though we standardized the season of omalizumab treatment and blood collection, 
 
328 we believe that the positive correlation observed between changes in allergen-specific 
 
329 IgE after omalizumab treatment and baseline levels of allergen-specific IgE would not 
 
330 change. 
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331 In conclusion, we found that the changes in allergen-specific IgE after omalizumab 
 
332 treatment were dependent on the baseline levels of allergen-specific IgE. In addition, we 
 
333 also found that all patients with negative-to-positive seroconversion for cedar-specific 
 
334 IgE due to omalizumab treatment had cedar pollinosis before beginning omalizumab 
 
335 treatment. These findings suggest that allergen-specific IgE can play a critical role in 
 
336 allergic diseases despite being under the detectable level. Further larger-scale studies are 
 
337 
 
338 
 
339 
needed to validate our data. 
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457 Tables and Figure Legends 
 
458 
 
459 
Table 1: Patient demographics 
 
460 
 
461 
Table 2: Mean changes in tIgE and sIgE after omalizumab 
 
462 
 
463 
Table 3: Correlation between ∆tIgE and ∆sIgE 
 
464 Fig.  1:  Allergen-specific  IgE  positivity  in  patients  before  omalizumab  treatment 
 
465 measured using ImmunoCAP-FEIA   (N=47). Sensitization was defined as an 
 
466 
 
467 
allergen-specific IgE level >0.35 kU/L. Values are shown above the bars. 
 
468 Fig.  2:  Percent  increase  in  allergen-specific  IgE  levels  by  class  category  after 
 
469 
 
470 
omalizumab treatment (N=47). Values are shown above the bars. 
 
471 Fig.  3:  Correlation  between  allergen-specific  IgE  positivity  before  omalizumab 
 
472 treatment and the percent increase in allergen-specific IgE levels by class category after 
 
473 omalizumab treatment (A). The correlation between allergen-specific IgE levels before 
 
474 omalizumab  treatment  and  the  mean  change  in  allergen-specific  IgE  levels  after 
 
475 
 
476 
omalizumab treatment (B) 
 
477 Fig. 4: Percentage of negative-to-positive seroconversion rates for allergen-specific IgE. 
 
478 Raw data are shown above the bars. Raw numbers were shown above the bars in 
 
479 
 
480 
boldface. 
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